553 related articles for article (PubMed ID: 33823168)
21. Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting.
Carey N; Leahy J; Trela-Larsen L; Mc Cullagh L; Barry M
J Mark Access Health Policy; 2023; 11(1):2166375. PubMed ID: 36684853
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
23. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
Lin JK; Lerman BJ; Barnes JI; Boursiquot BC; Tan YJ; Robinson AQL; Davis KL; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2018 Nov; 36(32):3192-3202. PubMed ID: 30212291
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain.
Ribera Santasusana JM; de Andrés Saldaña A; García-Muñoz N; Gostkorzewicz J; Martínez Llinàs D; Díaz de Heredia C
Clinicoecon Outcomes Res; 2020; 12():253-264. PubMed ID: 32523362
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
30. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.
Bastos-Oreiro M; de Las Heras A; Presa M; Casado MA; Pardo C; Martín-Escudero V; Sureda A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158805
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Goto H; Makita S; Kato K; Tokushige K; Fujita T; Akashi K; Izutsu K; Teshima T
Int J Clin Oncol; 2020 Sep; 25(9):1736-1743. PubMed ID: 32448949
[TBL] [Abstract][Full Text] [Related]
34. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract][Full Text] [Related]
35. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
Matasar M; Masaquel A; S Ho R; Launonen A; Ng CD; Wang R; Fox D; Hossain F; Li J; Burke JM
J Med Econ; 2023; 26(1):1134-1144. PubMed ID: 37674384
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
38. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of polatuzumab-bendamustine-rituximab
Calamia M; McBride A; Abraham I
J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
[TBL] [Abstract][Full Text] [Related]
40. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
Perales MA; Kuruvilla J; Snider JT; Vadgama S; Blissett R; El-Moustaid F; Smith NJ; Patel AR; Johnston PB
Transplant Cell Ther; 2022 Nov; 28(11):750.e1-750.e6. PubMed ID: 35970302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]